Cargando…

RF32 | PSUN49 To Repeat or Not to Repeat: The Question of Aldosterone and Renin Variability

Plasma aldosterone concentration (PAC), renin levels and aldosterone-renin ratio (ARR) are used to screen for primary aldosteronism (PA). A recent study (Yozamp et al. Hypertension 2021) reported substantial intraindividual variability of PAC and ARR (using plasma renin activity) in the context of u...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Elisabeth, Gwini, StellaMay, Libianto, Renata, Choy, Kay Weng, Fuller, Peter, Shen, Jimmy, Yang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624878/
http://dx.doi.org/10.1210/jendso/bvac150.533
_version_ 1784822344922955776
author Ng, Elisabeth
Gwini, StellaMay
Libianto, Renata
Choy, Kay Weng
Fuller, Peter
Shen, Jimmy
Yang, Jun
author_facet Ng, Elisabeth
Gwini, StellaMay
Libianto, Renata
Choy, Kay Weng
Fuller, Peter
Shen, Jimmy
Yang, Jun
author_sort Ng, Elisabeth
collection PubMed
description Plasma aldosterone concentration (PAC), renin levels and aldosterone-renin ratio (ARR) are used to screen for primary aldosteronism (PA). A recent study (Yozamp et al. Hypertension 2021) reported substantial intraindividual variability of PAC and ARR (using plasma renin activity) in the context of usual antihypertensive therapy. The intraindividual variability of PAC and direct renin concentration (DRC), a more widely used measurement of renin, in the absence of interfering medications is unknown but important where a single ARR is used to screen for PA. The aim of this study was to evaluate the intraindividual variability of PAC, DRC and ARR in a cohort of patients with and without PA. Patients who attended an Endocrine Hypertension Service from May 2017 to July 2021 with at least two ARR measurements off interfering medications were retrospectively evaluated. While the measurements were performed at several hospital and community laboratories, the same analyser was used. PA was confirmed using the seated saline suppression test following an abnormal ARR >70 pmol/L: mU/L. PAC and DRC variability was calculated as coefficient of variation (CV=standard deviation/mean×100) and percent difference (PD=difference between highest and lowest values/mean×100). A total of 223 patients were analysed (55% female, median age 52 years), including 162 with PA (25% with unilateral disease). Significant variability in both PAC and DRC was observed in the PA group (CV: 24%, 41%; PD: 46%, 76% respectively) and non-PA group (CV: 22%, 40%; PD: 38%, 65% respectively), which was higher than the assays’ analytical variability. The ARR was also highly variable within individuals, in both the PA group (CV: 42%; PD: 74%) and non-PA group (CV: 37%; PD: 61%). Variability was not significantly different between PA subtypes, and persisted irrespective of age, gender and degree of hypertension. Sixty-two patients (39%) with PA could have had a missed diagnosis if the ARR had not been repeated, i.e., had at least one ARR <70 pmol/L: mU/L, while 28 (46%) without PA had at least one abnormal ARR > 70. Intraindividual variability in PAC, DRC and ARR occurs in a significant number of patients being investigated for PA. These results support the need for at least two ARR on separate occasions before PA is excluded or further investigated. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m., Monday, June 13, 2022 1:06 p.m. - 1:11 p.m.
format Online
Article
Text
id pubmed-9624878
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96248782022-11-14 RF32 | PSUN49 To Repeat or Not to Repeat: The Question of Aldosterone and Renin Variability Ng, Elisabeth Gwini, StellaMay Libianto, Renata Choy, Kay Weng Fuller, Peter Shen, Jimmy Yang, Jun J Endocr Soc Cardiovascular Endocrinology Plasma aldosterone concentration (PAC), renin levels and aldosterone-renin ratio (ARR) are used to screen for primary aldosteronism (PA). A recent study (Yozamp et al. Hypertension 2021) reported substantial intraindividual variability of PAC and ARR (using plasma renin activity) in the context of usual antihypertensive therapy. The intraindividual variability of PAC and direct renin concentration (DRC), a more widely used measurement of renin, in the absence of interfering medications is unknown but important where a single ARR is used to screen for PA. The aim of this study was to evaluate the intraindividual variability of PAC, DRC and ARR in a cohort of patients with and without PA. Patients who attended an Endocrine Hypertension Service from May 2017 to July 2021 with at least two ARR measurements off interfering medications were retrospectively evaluated. While the measurements were performed at several hospital and community laboratories, the same analyser was used. PA was confirmed using the seated saline suppression test following an abnormal ARR >70 pmol/L: mU/L. PAC and DRC variability was calculated as coefficient of variation (CV=standard deviation/mean×100) and percent difference (PD=difference between highest and lowest values/mean×100). A total of 223 patients were analysed (55% female, median age 52 years), including 162 with PA (25% with unilateral disease). Significant variability in both PAC and DRC was observed in the PA group (CV: 24%, 41%; PD: 46%, 76% respectively) and non-PA group (CV: 22%, 40%; PD: 38%, 65% respectively), which was higher than the assays’ analytical variability. The ARR was also highly variable within individuals, in both the PA group (CV: 42%; PD: 74%) and non-PA group (CV: 37%; PD: 61%). Variability was not significantly different between PA subtypes, and persisted irrespective of age, gender and degree of hypertension. Sixty-two patients (39%) with PA could have had a missed diagnosis if the ARR had not been repeated, i.e., had at least one ARR <70 pmol/L: mU/L, while 28 (46%) without PA had at least one abnormal ARR > 70. Intraindividual variability in PAC, DRC and ARR occurs in a significant number of patients being investigated for PA. These results support the need for at least two ARR on separate occasions before PA is excluded or further investigated. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m., Monday, June 13, 2022 1:06 p.m. - 1:11 p.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9624878/ http://dx.doi.org/10.1210/jendso/bvac150.533 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cardiovascular Endocrinology
Ng, Elisabeth
Gwini, StellaMay
Libianto, Renata
Choy, Kay Weng
Fuller, Peter
Shen, Jimmy
Yang, Jun
RF32 | PSUN49 To Repeat or Not to Repeat: The Question of Aldosterone and Renin Variability
title RF32 | PSUN49 To Repeat or Not to Repeat: The Question of Aldosterone and Renin Variability
title_full RF32 | PSUN49 To Repeat or Not to Repeat: The Question of Aldosterone and Renin Variability
title_fullStr RF32 | PSUN49 To Repeat or Not to Repeat: The Question of Aldosterone and Renin Variability
title_full_unstemmed RF32 | PSUN49 To Repeat or Not to Repeat: The Question of Aldosterone and Renin Variability
title_short RF32 | PSUN49 To Repeat or Not to Repeat: The Question of Aldosterone and Renin Variability
title_sort rf32 | psun49 to repeat or not to repeat: the question of aldosterone and renin variability
topic Cardiovascular Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624878/
http://dx.doi.org/10.1210/jendso/bvac150.533
work_keys_str_mv AT ngelisabeth rf32psun49torepeatornottorepeatthequestionofaldosteroneandreninvariability
AT gwinistellamay rf32psun49torepeatornottorepeatthequestionofaldosteroneandreninvariability
AT libiantorenata rf32psun49torepeatornottorepeatthequestionofaldosteroneandreninvariability
AT choykayweng rf32psun49torepeatornottorepeatthequestionofaldosteroneandreninvariability
AT fullerpeter rf32psun49torepeatornottorepeatthequestionofaldosteroneandreninvariability
AT shenjimmy rf32psun49torepeatornottorepeatthequestionofaldosteroneandreninvariability
AT yangjun rf32psun49torepeatornottorepeatthequestionofaldosteroneandreninvariability